StockData
QuidelOrtho Corp logo

QuidelOrtho Corp (QDEL) stock

QDELNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends January 1
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/3063% below fair value
$9.57−0.30 (-3.04%)

Close on Nov 18, 2026Market cap $656.27MP/E –Yield –

QuidelOrtho operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

QuidelOrtho's operating cash flow for the twelve months ending Sep 27, 2026 was $7.90M, down 78.6% year over year. For fiscal 2025 it was $105.20M, up 26.7% from the year before. The highest annual figure on record is $885.30M in fiscal 2022.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 28, 2025$105.20M+26.7%
FY2024Dec 29, 2024$83.00M-70.4%
FY2023Dec 31, 2023$280.20M-68.3%
FY2022Jan 1, 2023$885.30M+9.9%
FY2021Jan 2, 2022$805.90M+28.0%
FY2020Jan 3, 2021$629.70M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 27, 2026$19.60M–
Q2 FY2026Jun 28, 2026-$110.60M–
Q1 FY2026Mar 29, 2026-$33.00M-150.3%
Q4 FY2025Dec 28, 2025$131.90M+107.1%
Q3 FY2025Sep 28, 2025-$45.50M-138.6%
Q2 FY2025Jun 29, 2025-$46.80M–
Q1 FY2025Mar 30, 2025$65.60M–
Q4 FY2024Dec 29, 2024$63.70M-20.8%
Q3 FY2024Sep 29, 2024$117.90M+184.1%
Q2 FY2024Jun 30, 2024-$97.90M–
Q1 FY2024Mar 31, 2024-$700.00K-100.4%
Q4 FY2023Dec 31, 2023$80.40M-52.5%
Q3 FY2023Oct 1, 2023$41.50M–
Q2 FY2023Jul 2, 2023-$30.60M-113.6%
Q1 FY2023Apr 2, 2023$188.90M-62.3%
Q4 FY2022Jan 1, 2023$169.40M-47.3%
Q3 FY2022Oct 2, 2022-$9.70M-112.6%
Q2 FY2022Jul 3, 2022$224.70M–
Q1 FY2022Apr 3, 2022$500.90M–
Q4 FY2021Jan 2, 2022$321.40M–
Q3 FY2021Oct 3, 2021$77.00M–

More QuidelOrtho figures

See a number that looks wrong?